Evidence map›Paper›PMID 35661835›Full record

ArticleBone marrow transplantation2022

Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.

Masaharu Tamaki, Shimpei Matsumi, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Masaharu Tamaki *Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-5899-7913
Shimpei Matsumi *Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Hideki NakasoneDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-5812-9315
Yuhei NakamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Masakatsu KawamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Shunto KawamuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Junko TakeshitaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Nozomu YoshinoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Yukiko MisakiDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Kazuki YoshimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-8013-1400
Ayumi GomyoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Aki TaniharaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Yosuke OkadaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Machiko KusudaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Kazuaki KamedaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Shun-Ichi KimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0001-9827-8526
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-2635-3395
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. ycanda-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-4866-9307
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-melanoma differentiation-associated gene 5 (MDA5) antibody is one of auto-immune antibodies which is associated with a rare subtype of dermatomyositis (DM), and MDA5-DM is well-characterized by rapid progressive interstitial lung disease (ILD) which in part resembles pulmonary complications after allogeneic hematopoietic cell transplantation (allo-HCT). However, previous studies about anti-MDA5 antibody after allo-HCT were extremely limited. Here, we present 4 cases of ILD with anti-MDA5 antibody after allo-HCT. All of the cases showed rapidly progressive clinical course and 3 of 4 cases died despite intensive immunosuppressive therapies which included prednisolone, cyclophosphamide and calcineurin inhibitor. Additionally, 3 of 4 cases had tested positive for anti-MDA5 antibody by using cryopreserved plasma which were collected about 2-3 months before the diagnosis of MDA5-DM-ILD. It suggests that an inflammatory condition due to MDA5-DM-ILD might have sub-clinically occurred before the development of respiratory failure. The current cases suggest that the clinical feature was relatively similar to classical MDA5-DM-ILD, although it is difficult to distinguish MDA5-DM-ILD from chronic GVHD and other pulmonary complications after allo-HCT. Since clinical courses of MDA5-DM-ILD is considerably aggressive, it is important to discriminate MDA5-DM-ILD from other complications after allo-HCT.

Indexed as

DermatomyositisHematopoietic Stem Cell TransplantationLung Diseases, InterstitialAutoantibodiesHumansInterferon-Induced Helicase, IFIH1PrognosisRetrospective StudiesAutoantibodiesInterferon-Induced Helicase, IFIH1

Identifiers

PMID35661835
PMCPMC9166177
OpenAlexW4281910727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.